HVNI Ambulation Feasibility Study
Status: | Completed |
---|---|
Conditions: | Cardiology, Pulmonary, Pulmonary |
Therapuetic Areas: | Cardiology / Vascular Diseases, Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/3/2019 |
Start Date: | November 21, 2018 |
End Date: | March 11, 2019 |
Assessing Clinical Effect of HVNI on Patient Ambulation in Acute Care Scenarios: a Feasibility Study
The pilot/feasibility study evaluates the ability of High Velocity Nasal Insufflation (HVNI)
therapy to facilitate ambulation and mobilization in patients experiencing shortness of
breath, as compared to simple oxygen therapy.
therapy to facilitate ambulation and mobilization in patients experiencing shortness of
breath, as compared to simple oxygen therapy.
The hypothesis is that HVNI therapy, when implemented in conjunction to ambulatory practices,
will be more effective than TAU to improve patient mobility by reducing the patient's
perceived dyspnea and exertion via maintaining oxygenation (reduced desaturation) and
supporting ventilation (reduced work of breathing [WOB]). The primary endpoint is exercise
performance, defined as the distance and duration of patient ambulation.
To provide a sample data set, The investigators will enroll up to 32 subjects to complete
this feasibility assessment, with a calculated sample size of N=26 plus a 20% failure rate.
This will provide sufficient initial data to inform the appropriate sample size of a
follow-on randomized study.
This will be a feasibility study, performed as a prospective, crossover controlled trial to
evaluate the potential patient improvement during ambulation while on HVNI relative to TAU.
Patients who fit the criteria for inclusion will perform ambulation for each study arm: the
control arm (TAU) followed by the test arm (HVNI). Control group will receive the site TAU
(not HVNI), and the test group will receive HVNI therapy. In both cases the clinical
management will otherwise remain unchanged based on the site SOC practices. The patient FiO2
and flow values will be recorded while on any supplemental oxygen. Subjects will wear
appropriate gear and, when applicable, have mobile carts to provide supplemental oxygen
therapy (e.g. HVNI VTU) during ambulation. If they meet criteria for intubation or are deemed
to need intubation by the critical care team, they will undergo prompt intubation and be
managed according to standard practice. After each of the study arms, the clinicians will
complete perception score assessments.
will be more effective than TAU to improve patient mobility by reducing the patient's
perceived dyspnea and exertion via maintaining oxygenation (reduced desaturation) and
supporting ventilation (reduced work of breathing [WOB]). The primary endpoint is exercise
performance, defined as the distance and duration of patient ambulation.
To provide a sample data set, The investigators will enroll up to 32 subjects to complete
this feasibility assessment, with a calculated sample size of N=26 plus a 20% failure rate.
This will provide sufficient initial data to inform the appropriate sample size of a
follow-on randomized study.
This will be a feasibility study, performed as a prospective, crossover controlled trial to
evaluate the potential patient improvement during ambulation while on HVNI relative to TAU.
Patients who fit the criteria for inclusion will perform ambulation for each study arm: the
control arm (TAU) followed by the test arm (HVNI). Control group will receive the site TAU
(not HVNI), and the test group will receive HVNI therapy. In both cases the clinical
management will otherwise remain unchanged based on the site SOC practices. The patient FiO2
and flow values will be recorded while on any supplemental oxygen. Subjects will wear
appropriate gear and, when applicable, have mobile carts to provide supplemental oxygen
therapy (e.g. HVNI VTU) during ambulation. If they meet criteria for intubation or are deemed
to need intubation by the critical care team, they will undergo prompt intubation and be
managed according to standard practice. After each of the study arms, the clinicians will
complete perception score assessments.
Inclusion Criteria:
- Adults over the age of 18 years
- Demonstrated respiratory distress upon mild to moderate exertion (e.g. dyspnea upon
standing, walking, etc.)
- Candidate for clinical ambulation/mobilization
Exclusion Criteria:
- Hypoxemia at resting baseline: unable to maintain SpO2≥88% with supplemental oxygen
- Inability to provide informed consent
- Pregnancy
- Known contraindication to perform ambulation, per site SOC practices
- Inadequate respiratory drive or any known contraindications to HVNI
- Inability to use nasal cannula and HVNI therapy
- Agitation or uncooperativeness
- Determined by the attending clinician to be sufficiently unstable or unsuitable for
this feasibility study
We found this trial at
3
sites
1330 Coshocton Ave
Mount Vernon, Ohio 43050
Mount Vernon, Ohio 43050
(740) 393-9000
Principal Investigator: Shailesh Patel, MD
Phone: 740-397-0770
Knox Community Hospital A community-owned, 115-bed, not-for-profit hospital located in Mount Vernon, Ohio (approximately 40...
Click here to add this to my saved trials
Newport News, Virginia 23601
Principal Investigator: Paragkumar Amin, MD
Phone: 757-594-2000
Click here to add this to my saved trials
Saint Charles, Missouri 63301
Principal Investigator: Thomas M Siler, MD
Phone: 636-946-1650
Click here to add this to my saved trials